Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
15 July 2021Website:
http://www.sightsciences.comNext earnings report:
07 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | 93 min agoDividend
Analysts recommendations
Institutional Ownership
SGHT Latest News
MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it will present at the upcoming Piper Sandler 36th Annual Healthcare Conference, in New York, NY.
Sight Sciences, Inc. (NASDAQ:SGHT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder & Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matt Link - Chief Commercial Officer Conference Call Participants Macauley Kilbane - William Blair Phil Dantoin - Piper Sandler Nelson Cox - Lake Street Capital Markets Tom Stephan - Stifel Operator Thank you for standing by. My name is Janine, I will be your conference operator for today.
MENLO PARK, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the third quarter ended September 30, 2024, after the market close on Thursday, November 7, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
The study found improvements in reading speed, vision-related quality of life, and suggested potential benefits of an interventional approach for patients with dry eye disease The study found improvements in reading speed, vision-related quality of life, and suggested potential benefits of an interventional approach for patients with dry eye disease
Sight Sciences, Inc. (NASDAQ:SGHT ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matthew Link - Chief Commercial Officer Conference Call Participants Thomas Stephan - Stifel Joseph Conway - Needham & Company Felipe Lamar - Citi Operator Good day, and thank you for standing by. Welcome to the Sight Sciences Second Quarter 2024 Earnings Results Conference Call.
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.30 per share a year ago.
MENLO PARK, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the second quarter ended June 30, 2024, after the market close on Thursday, August 1, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
The Sustainability Report provides data for 2021 through 2023 on the Company's environmental, social, and governance initiatives The Sustainability Report provides data for 2021 through 2023 on the Company's environmental, social, and governance initiatives
Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvements in the signs and symptoms of dry eye disease through month twelve. Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvements in the signs and symptoms of dry eye disease through month twelve.
The analysis published in Clinical Ophthalmology suggests that OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma as it was in mild and moderate glaucoma. The analysis published in Clinical Ophthalmology suggests that OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma as it was in mild and moderate glaucoma.
- 1(current)
What type of business is Sight Sciences?
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
What sector is Sight Sciences in?
Sight Sciences is in the Healthcare sector
What industry is Sight Sciences in?
Sight Sciences is in the Medical Devices industry
What country is Sight Sciences from?
Sight Sciences is headquartered in United States
When did Sight Sciences go public?
Sight Sciences initial public offering (IPO) was on 15 July 2021
What is Sight Sciences website?
https://www.sightsciences.com
Is Sight Sciences in the S&P 500?
No, Sight Sciences is not included in the S&P 500 index
Is Sight Sciences in the NASDAQ 100?
No, Sight Sciences is not included in the NASDAQ 100 index
Is Sight Sciences in the Dow Jones?
No, Sight Sciences is not included in the Dow Jones index
When was Sight Sciences the previous earnings report?
No data
When does Sight Sciences earnings report?
The next expected earnings date for Sight Sciences is 07 March 2025